We are pleased to announce that one of our Directors, David Heal, along with Judy Ashworth, VP of Rx Strategic Services and CMO, Pinney Associates Inc, have been appointed as Scientific Advisors to Sintalica Bioscience, a company developing novel psychedelic treatments for chronic pain. This marks another successful collaboration where the complementary skills of DevelRx and Pinney Associates, in the non-clinical and clinical development of CNS-active drugs, can be used to benefit our clients.
Please contact us for further information about our experience and expertise in the area of psychedelic drug development.